Lyon-based MaaT Pharma announced the appointment of Nathalie Corvaïa, Ph.D., as Chief Scientific Officer. She brings more than 20 years of experience leading drug discovery and development programs in oncology and guiding the advancement of product candidates into the clinic.

Prior to joining MaaT Pharma, Corvaïa was the Head of Immuno-oncology Research at The Pierre Fabre Immunology Center (CIPF) in France. She was responsible for the institute’s research activities in immuno-oncology from early-stage product discovery to Phase 1 entry, including GMP production of its products including biologics and live products. In her previous roles as Managing Director and Research Director, she led several diverse research teams contributing to a growing pipeline of products currently in preclinical and clinical trials in different tumor indications. Corvaïa did her postdoctoral research in cellular immunology at Novartis in Austria and obtained a PhD degree in Cellular Immunology at St. Louis Hospital in Paris, France. She has authored over 100 scientific publications and holds several issued patents and is also an active member of the American Association for Cancer Research (AACR).